查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1744575

2032 年心房颤动市场预测：按产品类型、疗法、技术、最终用户和地区进行的全球分析

Atrial Fibrillation Market Forecasts to 2032 - Global Analysis By Product (Surgical Devices, Non-Surgical Devices and Pharmacological Drugs), Type, Treatment, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球心房颤动市场预计在 2025 年达到 176 亿美元，到 2032 年将达到 273 亿美元，预测期内的复合年增长率为 6.5%。

心房颤动是一种心律不整，其特征是心房（心臟上腔）快速且不规则地跳动。当心房内的电讯号变得混乱并扰乱正常心律时，就会发生心房颤动。这会导致血液循环不良，并增加中风、心臟衰竭和其他心臟相关併发症的风险。常见症状包括心悸、疲劳、胸部不适和呼吸急促。早期诊断和药物治疗、生活方式改变和手术干预对于有效治疗至关重要。

根据美国国家生物技术资讯中心2021年发表的论文，估计全球心房颤动的患病人数约为3,750万人，预计到2050年将增加60.0%以上。

全球心血管疾病盛行率不断上升

心房颤动 (AFib) 盛行率的上升与人口老化和生活方式相关的风险因素有关。肥胖、高血压和糖尿病是心血管疾病负担加重的主要原因。对心房颤动症状的认识不断提高，促使人们能够更早进行诊断和治疗。久坐的生活方式和压力相关疾病进一步增加了心臟病的风险。诊断工具的进步使得人们能够更好地检测心房颤动病例。全球对有效心房颤动治疗的需求日益增长。

心房颤动治疗相关的风险和併发症

心导管电气烧灼术等心房颤动治疗有出血及感染风险。抗凝血剂会增加过度出血等副作用的风险。先进疗法费用高昂，许多患者难以负担。复杂的手术需要熟练的专业人员，而这类专业人员却十分稀缺。患者不坚持长期药物治疗也是另一个挑战。这些因素阻碍了心房颤动治疗的广泛应用。

微创治疗方法的发展

心导管电气烧灼术等微创治疗方法因其恢復时间更短而日益受到青睐。消融技术的创新提高了准确性和患者预后。不断增长的研究投入支持了更安全治疗方法的开发。用于即时心臟监测的可穿戴设备增强了早期疗育策略。医疗设备公司和医疗保健提供者之间的合作推动了创新。这些进步为心房颤动市场创造了巨大的成长机会。

医疗设备製造商之间的激烈竞争

心房颤动治疗市场面临各大医疗设备公司之间的激烈竞争。快速的技术进步迫使製造商不断创新。规模较小的企业难以与提供先进解决方案的知名品牌竞争。价格战和成本削减策略影响利润率。新设备核准的监管障碍阻碍了新设备的市场进入。激烈的竞争可能导致市场饱和，从而限制新参与企业的成长。

COVID-19的影响：

由于医院资源紧张，COVID-19疫情导致选择性心房颤动治疗中断。远端医疗的应用激增，使得对心房颤动患者进行远端监控成为可能。供应链问题影响了关键医疗设备的供应。疫情凸显了高风险患者早期发现心房颤动的重要性。后疫情时代，医疗支出的增加加速了市场復苏。人们对心臟健康的认识不断提高，持续推动对心房颤动治疗的需求。

阵发性心房颤动细分市场预计将成为预测期内最大的细分市场

由于阵发性心房颤动在确诊病例中盛行率较高，预计该领域将在预测期内占据最大的市场占有率。其间歇性特征推动了对早期诊断和治疗方案的需求。穿戴式监测设备的进步有助于及时发现阵发性心房颤动。患者对微创治疗的偏好推动了该领域的成长。医疗保健可近性的提高有助于对阵发性心房颤动进行早期疗育。该领域正受益于标靶治疗的持续研究。

预计医疗治疗领域在预测期内将实现最高的复合年增长率。

预计药物治疗领域将在预测期内达到最高成长率。抗凝血剂和抗心律不整药物在控制心房颤动症状方面仍然至关重要。对新型药物製剂的持续研究正在提高治疗效果。患者对非侵入性治疗的偏好推动了对药物解决方案的需求。新兴市场医疗保健可近性的提高也支持了该领域的成长。个人化医疗的创新将进一步加速药物治疗的普及。

占比最大的地区：

在预测期内，亚太地区预计将占据最大的市场占有率，这得益于其庞大的老龄化人口和不断增长的房颤患者数量。中国和印度等国家医疗支出的增加正在推动市场成长。该地区不断扩大的医疗基础设施为先进的房颤治疗提供支援。人们对心血管健康的认识不断提高，刺激了对诊断工具的需求。政府为改善医疗保健可近性而采取的措施增强了市场潜力。大型医疗设备製造商的存在增强了该地区的主导地位。

复合年增长率最高的地区：

在预测期内，北美预计将凭藉其先进的医疗体系实现最高的复合年增长率。心导管电气烧灼术等创新型心房颤动治疗手段的广泛采用正在推动市场扩张。该地区高度重视研发，推动技术进步。生活方式相关风​​险因素的日益增加导致心房颤动患者数量增加。支持性报销政策增加了患者获得治疗的机会。主要企业之间的策略伙伴关係将进一步推动市场成长。

免费客製化服务：

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球心房颤动市场（按产品）

  • 手术设备
  • 非手术器械
  • 药理药物

6. 全球心房颤动市场（按类型）

  • 阵发性心房颤动
  • 持续性心房颤动
  • 永久性心房颤动

7. 全球心房颤动市场（依治疗方法）

  • 药物治疗
  • 电去心房颤动
  • 心导管电气烧灼术
  • 外科手术

8. 全球心房颤动市场（按技术）

  • 射频
  • 雷射
  • 冷冻疗法
  • 其他技术

9. 全球心房颤动市场（依最终用户）

  • 医院
  • 门诊手术中心
  • 心导管实验室
  • 其他最终用户

第 10 章全球心房颤动市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Abbott Laboratories
  • MicroPort
  • CardiacSense
  • Biosense Webster
  • AtriCure
  • LivaNova
  • Johnson and Johnson
  • ZOLL Medical
  • ACBIO
  • Medtronic
  • Biotronik
  • Philips Healthcare
  • Stereotaxis
  • Boston Scientific
  • Siemens Healthineers
Product Code: SMRC29623

According to Stratistics MRC, the Global Atrial Fibrillation Market is accounted for $17.6 billion in 2025 and is expected to reach $27.3 billion by 2032 growing at a CAGR of 6.5% during the forecast period. Atrial fibrillation is a heart rhythm disorder characterized by rapid and irregular beating of the atria, the upper chambers of the heart. It occurs when electrical signals in the atria become chaotic, disrupting the normal rhythm. This leads to poor blood circulation and increases the risk of stroke, heart failure, and other heart-related complications. Common symptoms include palpitations, fatigue, chest discomfort, and shortness of breath. Early diagnosis and management through medication, lifestyle changes, or surgical intervention are essential for effective treatment.

According to an article published in the National Center for Biotechnology Information in 2021, the prevalence of atrial fibrillation is estimated to be around 37.5 million across the globe and is projected to increase by more than 60.0% by the year 2050.

Market Dynamics:

Driver:

Increasing global prevalence of cardiovascular disorders

The rising incidence of atrial fibrillation (AFib) is linked to aging populations and lifestyle-related risk factors. Obesity, hypertension, and diabetes significantly contribute to the growing burden of cardiovascular diseases. Increased awareness of AFib symptoms prompts early diagnosis and treatment. Sedentary lifestyles and stress-related conditions further elevate the risk of heart disorders. Advancements in diagnostic tools enable better detection of AFib cases. The global demand for effective AFib treatments continues to rise.

Restraint:

Risks and complications associated with AFib treatments

AFib treatments, such as catheter ablation, carry risks of bleeding and infection. Anticoagulant medications increase the likelihood of adverse effects like excessive bleeding. High costs of advanced treatments limit accessibility for many patients. The complexity of procedures requires highly skilled professionals, which can be scarce. Patient non-compliance with long-term medication regimens poses additional challenges. These factors collectively hinder the widespread adoption of AFib therapies.

Opportunity:

Development of minimally invasive treatment options

Minimally invasive procedures like catheter ablation are gaining traction for their reduced recovery times. Innovations in ablation technologies improve precision and patient outcomes. Growing investment in research supports the development of safer treatment methods. Wearable devices for real-time heart monitoring enhance early intervention strategies. Collaborations between medical device companies and healthcare providers drive innovation. These advancements create significant growth opportunities in the AFib market.

Threat:

Intense competition among medical device manufacturers

The AFib treatment market faces fierce competition among leading medical device companies. Rapid technological advancements pressure manufacturers to innovate continuously. Smaller players struggle to compete with established brands offering advanced solutions. Price wars and cost-cutting strategies impact profit margins. Regulatory hurdles for new device approvals slow market entry. Intense competition may lead to market saturation, limiting growth for new entrants.

Covid-19 Impact:

The COVID-19 pandemic disrupted elective AFib procedures due to hospital resource constraints. Telemedicine adoption surged, enabling remote monitoring of AFib patients. Supply chain issues affected the availability of critical medical devices. The pandemic highlighted the importance of early AFib detection in high-risk patients. Post-COVID, increased healthcare spending has accelerated market recovery. Growing awareness of heart health continues to drive demand for AFib treatments.

The paroxysmal atrial fibrillation segment is expected to be the largest during the forecast period

The paroxysmal atrial fibrillation segment is expected to account for the largest market share during the forecast period, due to its high prevalence among diagnosed cases. Its intermittent nature drives demand for early diagnostic and treatment solutions. Advances in wearable monitoring devices aid in the timely detection of paroxysmal AFib. Patient preference for minimally invasive treatments boosts segment growth. Increased healthcare access supports early intervention for paroxysmal cases. The segment benefits from ongoing research into targeted therapies.

The drug therapy segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the drug therapy segment is predicted to witness the highest growth rate, due to its affordability and widespread availability. Anticoagulants and antiarrhythmic drugs remain critical for managing AFib symptoms. Ongoing research into novel drug formulations enhances treatment efficacy. Patient preference for non-invasive options drives demand for pharmaceutical solutions. Improved access to healthcare in emerging markets supports segment growth. Innovations in personalized medicine further accelerate the adoption of drug therapies.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its large aging population and rising AFib cases. Increasing healthcare expenditure in countries like China and India drives market growth. The region's expanding medical infrastructure supports advanced AFib treatments. Growing awareness of cardiovascular health boosts demand for diagnostic tools. Government initiatives to improve healthcare access enhance market potential. The presence of key medical device manufacturers strengthens the region's dominance.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, due to its advanced healthcare systems. High adoption of innovative AFib treatments like catheter ablation fuels market expansion. The region's strong focus on research and development drives technological advancements. Rising prevalence of lifestyle-related risk factors increases AFib cases. Supportive reimbursement policies enhance patient access to treatments. Strategic partnerships among key players further accelerate market growth.

Key players in the market

Some of the key players in Atrial Fibrillation Market include Abbott Laboratories, MicroPort, CardiacSense, Biosense Webster, AtriCure, LivaNova, Johnson and Johnson, ZOLL Medical, ACBIO, Medtronic, Biotronik, Philips Healthcare, Stereotaxis, Boston Scientific, and Siemens Healthineers.

Key Developments:

In May 2025, Abbott Laboratories introduced the Amplify(TM) Catheter, a next-generation ablation system with enhanced precision for treating paroxysmal atrial fibrillation.

In April 2025, Medtronic launched the PulseSelect(TM) PFA System, a novel pulsed-field ablation technology for safer and faster AFib procedures, reducing patient recovery time.

In March 2025, Boston Scientific announced the POLARx(TM) FIT Cryoablation Balloon, designed for improved adaptability in complex AFib cases, enhancing procedural outcomes.

In February 2025, Philips Healthcare debuted an AI-powered ECG monitoring platform, CardioGuard, for real-time detection of atrial fibrillation in outpatient settings.

Products Covered:

  • Surgical Devices
  • Non-Surgical Devices
  • Pharmacological Drugs

Types Covered:

  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation
  • Permanent Atrial Fibrillation

Treatments Covered:

  • Drug Therapy
  • Cardioversion
  • Catheter Ablation
  • Surgical Procedures

Technologies Covered:

  • Radiofrequency
  • Laser
  • Cryotherapy
  • Other Technologies

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Catheterization Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Atrial Fibrillation Market, By Product

  • 5.1 Introduction
  • 5.2 Surgical Devices
  • 5.3 Non-Surgical Devices
  • 5.4 Pharmacological Drugs

6 Global Atrial Fibrillation Market, By Type

  • 6.1 Introduction
  • 6.2 Paroxysmal Atrial Fibrillation
  • 6.3 Persistent Atrial Fibrillation
  • 6.4 Permanent Atrial Fibrillation

7 Global Atrial Fibrillation Market, By Treatment

  • 7.1 Introduction
  • 7.2 Drug Therapy
  • 7.3 Cardioversion
  • 7.4 Catheter Ablation
  • 7.5 Surgical Procedures

8 Global Atrial Fibrillation Market, By Technology

  • 8.1 Introduction
  • 8.2 Radiofrequency
  • 8.3 Laser
  • 8.4 Cryotherapy
  • 8.5 Other Technologies

9 Global Atrial Fibrillation Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Ambulatory Surgical Centers
  • 9.4 Cardiac Catheterization Laboratories
  • 9.5 Other End Users

10 Global Atrial Fibrillation Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 MicroPort
  • 12.3 CardiacSense
  • 12.4 Biosense Webster
  • 12.5 AtriCure
  • 12.6 LivaNova
  • 12.7 Johnson and Johnson
  • 12.8 ZOLL Medical
  • 12.9 ACBIO
  • 12.10 Medtronic
  • 12.11 Biotronik
  • 12.12 Philips Healthcare
  • 12.13 Stereotaxis
  • 12.14 Boston Scientific
  • 12.15 Siemens Healthineers

List of Tables

  • Table 1 Global Atrial Fibrillation Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Atrial Fibrillation Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Atrial Fibrillation Market Outlook, By Surgical Devices (2024-2032) ($MN)
  • Table 4 Global Atrial Fibrillation Market Outlook, By Non-Surgical Devices (2024-2032) ($MN)
  • Table 5 Global Atrial Fibrillation Market Outlook, By Pharmacological Drugs (2024-2032) ($MN)
  • Table 6 Global Atrial Fibrillation Market Outlook, By Type (2024-2032) ($MN)
  • Table 7 Global Atrial Fibrillation Market Outlook, By Paroxysmal Atrial Fibrillation (2024-2032) ($MN)
  • Table 8 Global Atrial Fibrillation Market Outlook, By Persistent Atrial Fibrillation (2024-2032) ($MN)
  • Table 9 Global Atrial Fibrillation Market Outlook, By Permanent Atrial Fibrillation (2024-2032) ($MN)
  • Table 10 Global Atrial Fibrillation Market Outlook, By Treatment (2024-2032) ($MN)
  • Table 11 Global Atrial Fibrillation Market Outlook, By Drug Therapy (2024-2032) ($MN)
  • Table 12 Global Atrial Fibrillation Market Outlook, By Cardioversion (2024-2032) ($MN)
  • Table 13 Global Atrial Fibrillation Market Outlook, By Catheter Ablation (2024-2032) ($MN)
  • Table 14 Global Atrial Fibrillation Market Outlook, By Surgical Procedures (2024-2032) ($MN)
  • Table 15 Global Atrial Fibrillation Market Outlook, By Technology (2024-2032) ($MN)
  • Table 16 Global Atrial Fibrillation Market Outlook, By Radiofrequency (2024-2032) ($MN)
  • Table 17 Global Atrial Fibrillation Market Outlook, By Laser (2024-2032) ($MN)
  • Table 18 Global Atrial Fibrillation Market Outlook, By Cryotherapy (2024-2032) ($MN)
  • Table 19 Global Atrial Fibrillation Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 20 Global Atrial Fibrillation Market Outlook, By End User (2024-2032) ($MN)
  • Table 21 Global Atrial Fibrillation Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 22 Global Atrial Fibrillation Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 23 Global Atrial Fibrillation Market Outlook, By Cardiac Catheterization Laboratories (2024-2032) ($MN)
  • Table 24 Global Atrial Fibrillation Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.